YD Bio Limited Ordinary Shares
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $435.7M
- Price
- $6.15
- % Change (Daily % change from the live per-ticker quote feed.)
- -13.50%
- Volume
- 439.7K
About
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Quick stats
Shares outstanding70.8M
Computed float1.4M
Float / shares2.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002011674
Websitehttps://www.ydesgroup.com
AI Summary
AI-generated1/12
minorbullishproduct launch
YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
YD Bio and merger partner EG BioMed launched an online AI Cancer Risk Assessment covering ten cancer types at a promotional price of US$10, reduced from a regular US$50.
The tool is a 52-question self-reported health survey producing low/moderate/high risk stratification, built on a 48-feature pan-cancer model plus ten cancer-specific models and a rule layer drawing on more than 140 published studies.
The Assessment sits upstream of EG BioMed US's CLIA-certified lab and the companies' telehealth platform, potentially funneling consumers toward physician-ordered blood tests. The companies also continue advancing their merger, announced via MOU in January 2026 and expected to close in 2026.
Red flags
- Product explicitly disclaims diagnosis, screening, early detection, or prediction value -- purely a wellness/risk-stratification tool
- Merger with EG BioMed remains subject to definitive agreements, closing conditions, and regulatory approvals
- Micro-cap with promotional-priced consumer product; revenue contribution likely immaterial near term